For two years, roughly a thousand women a year in England lived with a cruel arithmetic: a drug called Enhertu could extend their lives by months or years, yet the body charged with protecting NHS resources judged it too costly to provide. On Thursday, that judgment reversed — shifted not by compassion alone, but by a US trade deal that raised spending thresholds and new methods for measuring what a good year of life is worth. The change arrived as a relief to those still living, and as a reckoning for a system that asks the terminally ill to spend their remaining time campaigning for the righ
Enhertu breast cancer drug now available on NHS in England after two-year campaign
Thousands of patients with HER2-low metastatic breast cancer died while waiting for access to Enhertu during the two-year campaign period, including patient advocate Jeannie Ambrose.